Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study - The Lancet Oncology

Understanding Liquid Biopsy for Early Cancer Detection and Screening — BLOODPAC

Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK - The Lancet Oncology

Cancer care innovation: The multi-cancer early detection test leaders are implementing for detection

Multimodal cell-free DNA whole-genome analysis combined with TET-Assisted Pyridine Borane Sequencing is sensitive and reveals specific cancer signals

Full article: Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications - ScienceDirect

The Lancet Oncology Publishes Results from SYMPLIFY, The First Prospective Study of a Multi-Cancer Early Detection Test in a Symptomatic Patient Population - GRAIL

ctDNA Tests for Early Cancer Detection - Are We There Yet?

Jason Carey on LinkedIn: Black History Month

Multi-cancer Early Detection Test In Symptomatic Patients, 40% OFF

Jeffrey Venstrom, M.D. on LinkedIn: #esmo22

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study - The Lancet

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study - The Lancet

Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK

Modelled mortality benefits of multi-cancer early detection screening in England